Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8WWZ4
UPID:
ABCAA_HUMAN
Alternative names:
-
Alternative UPACC:
Q8WWZ4; C9JZH2; C9K035; Q6PIQ6; Q7Z2I9; Q7Z7P7; Q86TD2
Background:
ATP-binding cassette sub-family A member 10 (ABCA10) is identified as a probable transporter, playing a pivotal role in macrophage lipid transport and homeostasis. This protein is part of the ATP-binding cassette (ABC) transporters, a large family of proteins that transport various molecules across extra- and intra-cellular membranes.
Therapeutic significance:
Understanding the role of ATP-binding cassette sub-family A member 10 could open doors to potential therapeutic strategies. Its involvement in lipid transport and homeostasis positions it as a key player in metabolic processes, which could be targeted in diseases related to lipid metabolism.